- Home
- CTO vs KALV Comparison
CTO vs KALV Comparison
Compare CTO & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- KALV
- Stock Information
- Founded
- CTO 1902
- KALV N/A
- Country
- CTO United States
- KALV United States
- Employees
- CTO N/A
- KALV N/A
- Industry
- CTO Real Estate Investment Trusts
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- KALV Health Care
- Exchange
- CTO Nasdaq
- KALV Nasdaq
- Market Cap
- CTO 568.5M
- KALV 642.3M
- IPO Year
- CTO N/A
- KALV N/A
- Fundamental
- Price
- CTO $17.60
- KALV $14.31
- Analyst Decision
- CTO Strong Buy
- KALV Strong Buy
- Analyst Count
- CTO 3
- KALV 9
- Target Price
- CTO $22.33
- KALV $26.29
- AVG Volume (30 Days)
- CTO 399.4K
- KALV 2.0M
- Earning Date
- CTO 07-29-2025
- KALV 07-10-2025
- Dividend Yield
- CTO 8.63%
- KALV N/A
- EPS Growth
- CTO N/A
- KALV N/A
- EPS
- CTO N/A
- KALV N/A
- Revenue
- CTO $132,203,000.00
- KALV N/A
- Revenue This Year
- CTO $20.11
- KALV N/A
- Revenue Next Year
- CTO $8.51
- KALV $347.19
- P/E Ratio
- CTO N/A
- KALV N/A
- Revenue Growth
- CTO 17.48
- KALV N/A
- 52 Week Low
- CTO $16.12
- KALV $7.30
- 52 Week High
- CTO $21.15
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- CTO 44.45
- KALV 58.58
- Support Level
- CTO $17.11
- KALV $11.10
- Resistance Level
- CTO $17.57
- KALV $16.32
- Average True Range (ATR)
- CTO 0.37
- KALV 1.10
- MACD
- CTO -0.01
- KALV 0.36
- Stochastic Oscillator
- CTO 42.58
- KALV 68.95
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.